ZEMURON Drug Patent Profile

Which patents cover Zemuron, and what generic alternatives are available?

Zemuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in ZEMURON is rocuronium bromide. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zemuron

A generic version of ZEMURON was approved as rocuronium bromide by HOSPIRA on November 26^th, 2008.

Summary for ZEMURON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	17
Patent Applications:	1,346
DailyMed Link:	ZEMURON at DailyMed

Recent Clinical Trials for ZEMURON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Rijeka	N/A
McGill University Health Center	N/A
McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A

See all ZEMURON clinical trials

US Patents and Regulatory Information for ZEMURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-001	Mar 17, 1994		DISCN	Yes	No
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-002	Mar 17, 1994		DISCN	Yes	No
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-003	Mar 17, 1994		DISCN	Yes	No

Expired US Patents for ZEMURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-001	Mar 17, 1994
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-003	Mar 17, 1994
Organon Usa Inc	ZEMURON	rocuronium bromide	INJECTABLE;INJECTION	020214-002	Mar 17, 1994

International Patents for ZEMURON

See the table below for patents covering ZEMURON around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	89057
Finland	881707
Canada	1291117	DERIVES DE TYPE 2.beta.-MORPHOLINOANDROSTANE ET PROCEDES POUR LEUR PREPARATION (2BETA-MORPHOLINO-ANDROSTANE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION)

Supplementary Protection Certificates for ZEMURON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0287150	96C0038	Belgium		PRODUCT NAME: ROCURONIUMBROMIDE; NAT. REGISTRATION NO/DATE: 63 IS 9 F 12 19960709; FIRST REGISTRATION: NL RVG 16946 19940406

ZEMURON Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of ZEMURON (Rocuronium Bromide)

Introduction to ZEMURON

ZEMURON, also known as Rocuronium Bromide, is a neuromuscular blocking agent used to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a key player in the muscle relaxant drugs market, which is experiencing significant growth driven by various factors.

Market Size and Growth

The global muscle relaxant drugs market, which includes ZEMURON, was valued at USD 3.74 billion in 2022 and is expected to grow at a CAGR of 4.38% from 2023 to 2030, reaching USD 5.28 billion by 2030[1].

Segment Analysis

Drug Type

ZEMURON falls under the category of neuromuscular blocking agents, which are crucial for surgical procedures and intensive care. This segment is expected to contribute significantly to the overall market growth due to the increasing demand for muscle relaxants in surgical settings[1].

Route of Administration

The injectable segment, which includes ZEMURON, is anticipated to be the fastest-growing segment with a CAGR of 4.42% during the forecast period. This growth is driven by the preference for injectable muscle relaxants in clinical settings due to their rapid onset and efficacy[1].

Distribution Channels

Hospital Pharmacy

The hospital pharmacy segment captured the highest revenue share of 46.76% in 2022 and is expected to expand at the fastest CAGR over the forecast period. This dominance is attributed to growing awareness, increasing clinical and hospital visits, and the rising geriatric population, all of which drive the demand for muscle relaxants like ZEMURON[1].

Retail and Online Pharmacies

While hospital pharmacies lead the market, retail pharmacies and online pharmacies are also gaining prominence. Online pharmacies, in particular, offer convenience, comfort, and flexibility, which are attractive to patients[1].

Regional Outlook

North America

North America dominated the muscle relaxant drugs market with a share of 37.56% in 2022. This region's strong infrastructure, increasing incidence of chronic diseases, and significant government investments in healthcare contribute to its leading position[1].

Asia Pacific

The Asia Pacific region is estimated to witness the fastest growth due to rising demand for therapeutics, increasing R&D investments by governments, and rapid infrastructural development. Strategic activities by key market players, such as Eisai Co., Ltd.'s agreement to expand its presence in Asia, also drive regional growth[1].

Key Players and Strategic Activities

Companies like Zydus Cadila, which received USFDA approval for Cisatracurium Besylate Injection USP in 2020, are actively developing and commercializing new muscle relaxant products. Similarly, Caplin Point Laboratories received final approval for Rocuronium Bromide Injection in May 2023, highlighting the ongoing innovation and regulatory approvals in the market[1].

Financial Performance and Growth Drivers

Revenue Growth

The revenue from muscle relaxant drugs, including ZEMURON, is driven by several factors:

• Increasing Geriatric Population: Elderly individuals are more likely to be admitted to hospitals for chronic diseases, increasing the demand for muscle relaxants[1].
• Rising Musculoskeletal Disorders: The prevalence of musculoskeletal disorders is on the rise, contributing to the increased demand for muscle relaxants[4].
• COVID-19 Impact: Although the COVID-19 pandemic initially boosted demand for muscle relaxants due to their use in treating anxiety and improving sleep quality in patients, the market is expected to stabilize as COVID-19 cases decrease[4].

Regulatory Approvals and Funding

Regulatory approvals and funding for new products, such as the NIH grant awarded to Delpor, Inc. for its tizanidine implant product, further support the market's growth[4].

Examples and Statistics

• Gland Pharma Limited, a major player in the injectable market, reported a significant rise in revenue from operations, with a 56% increase to reach `56,647 million in FY 2023-24. This growth was partly driven by the successful introduction of new products, including muscle relaxants like Rocuronium Bromide[3].
• Zydus Cadila's commercialization of Cisatracurium Besylate Injection USP in 2020 is an example of the strategic activities by key players that are driving market growth[1].

Quotes from Industry Experts

"The increasing geriatric population and rising musculoskeletal disorders are key factors driving the growth of the muscle relaxant drugs market," - Industry Analyst[4].

Highlight and Citation

"The injectable segment is anticipated to be the fastest-growing segment of the muscle relaxant drugs market with a CAGR of 4.42% during the forecast period." - Grand View Research[1].

Key Takeaways

• The global muscle relaxant drugs market, including ZEMURON, is expected to grow at a CAGR of 4.38% from 2023 to 2030.
• The injectable segment, which includes ZEMURON, is the fastest-growing segment.
• Hospital pharmacies dominate the distribution channels, driven by growing awareness and increasing clinical visits.
• North America leads the market, while the Asia Pacific region is expected to witness the fastest growth.
• Regulatory approvals and funding for new products are key drivers of market growth.

FAQs

1. What is the expected growth rate of the muscle relaxant drugs market?

The muscle relaxant drugs market is expected to grow at a CAGR of 4.38% from 2023 to 2030[1].

2. Which segment is the fastest-growing in the muscle relaxant drugs market?

The injectable segment is anticipated to be the fastest-growing segment with a CAGR of 4.42% during the forecast period[1].

3. What are the key distribution channels for muscle relaxant drugs?

The key distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies capturing the highest revenue share[1].

4. Which region dominates the muscle relaxant drugs market?

North America dominates the market, accounting for 37.56% of the revenue share in 2022[1].

5. What are the major factors driving the growth of the muscle relaxant drugs market?

The growth is driven by the increasing geriatric population, rising musculoskeletal disorders, and strategic activities by key market players, along with regulatory approvals and funding for new products[1][4].

Sources Cited

1. Grand View Research - Muscle Relaxant Drugs Market Size & Share Report, 2030
2. Merck - Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
3. Gland Pharma Limited - Expanding Capabilities Accelerating Growth - Gland Pharma Limited
4. Mordor Intelligence - Muscle Relaxant Drugs Market Size & Share Analysis - Growth Trends